Standards on investor responsibility for human rights have evolved substantially over the past decade. Guidance including the UNGPs and OECD guidelines expect investors to clearly state, identify and address how they are respecting human rights within, and how they are using their influence over companies to ensure access to remedy. But how has this translated into action, what can we learn from the positive impacts and how can we mitigate the limitations?
Your panel for this episode includes:
Any securities mentioned during the podcast are not a recommendation to buy or sell.